CRITICAL Bio-Tech IGF-1 LR3 1mg (Vial – Mixing Water Included)

**IGF-1 LR3 (Insulin-like Growth Factor 1 – Long R3)** is a modified, long-acting analog of naturally occurring IGF-1, designed to significantly extend its half-life and systemic activity. It differs structurally from standard IGF-1 by the substitution of arginine at position 3 and the addition of a 13-amino-acid extension at the N-terminus. These modifications reduce its binding affinity to IGF-binding proteins (IGFBPs), allowing a greater proportion of the peptide to remain active in circulation for a longer duration—typically up to 20–30 hours compared to the much shorter lifespan of native IGF-1. Functionally, IGF-1 LR3 plays a central role in promoting anabolic processes within the body, including muscle growth, tissue repair, and nutrient partitioning. It enhances protein synthesis, increases glucose and amino acid uptake into cells, and supports the activation of satellite cells, which are critical for muscle fiber growth and regeneration. Unlike IGF-1 DES, which is known for its localized and short-lived effects, IGF-1 LR3 exerts a more systemic and prolonged influence, making it associated with whole-body anabolic signaling rather than site-specific activity. Due to its extended activity and potency, IGF-1 LR3 is often discussed in advanced research and performance contexts where sustained elevation of IGF-1 activity is desired. Its ability to bypass some of the natural regulatory constraints of endogenous IGF-1 can lead to more pronounced biological effects, but also requires careful consideration in terms of dosing, duration, and overall application. The longer half-life also means less frequent administration compared to shorter-acting variants. From a formulation and positioning perspective, IGF-1 LR3 is typically categorized as a high-impact, advanced peptide, often contrasted with upstream growth hormone secretagogues like Sermorelin. While upstream compounds stimulate natural hormone cascades, IGF-1 LR3 acts downstream, directly influencing cellular growth pathways. This positions it as a more aggressive and targeted option within the broader performance and recovery peptide landscape.